FXI vs XBI
iShares China Large-Cap ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.73% for FXI.
- • FXI pays a higher dividend yield (2.52%).
Side-by-side metrics
| Metric | FXI | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.73% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.52% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $6.07B | $8.30B |
YTD return | -2.09% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.55 | 1.09 |
P/E ratio | 10.22 | — |
Last price | $37.19 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
FXI top holdings
| 9988.HK | Alibaba Group Holding Ltd Ordinary Shares | 8.56% |
| 00939 | China Construction Bank Corp Class H | 8.30% |
| 0700.HK | Tencent Holdings Ltd | 7.69% |
| 01398 | Industrial And Commercial Bank Of China Ltd Class H | 6.08% |
| 1810.HK | Xiaomi Corp Class B | 5.41% |
| 3690.HK | Meituan Class B | 4.79% |
| 02318 | Ping An Insurance (Group) Co. of China Ltd Class H | 4.42% |
| 01211 | BYD Co Ltd Class H | 4.08% |
| 03988 | Bank Of China Ltd Class H | 3.75% |
| 9999.HK | NetEase Inc Ordinary Shares | 3.52% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About FXI
FXI (iShares China Large-Cap ETF) is Largest 50 Chinese companies. Managed by iShares, the fund carries $6.1B in assets under management, an expense ratio of 0.73%, a dividend yield of 2.52%. Its largest holding is Alibaba Group Holding Ltd Ordinary Shares (9988.HK), which represents 8.6% of the portfolio. Real Estate is the fund's largest sector exposure at 1.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.